Cytokinetics
company in South San Francisco, United States
CYTK Nasdaq
ISIN US23282W6057 SEC CIK 1061983 LEI 549300BE5DY1HW7IHA64
Follow Cytokinetics
Weekly email: filings, results
Revenue, last quarter
$47.6M
+2356.5% vs same quarter last year
Net income
−$190.1M
+37.9% vs same quarter last year
EPS, diluted
−$1.37
+46.3% vs same quarter last year
Operating cash flow
−$124M
−15.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $88M | −$785M |
| FY24 | $18.5M | −$589.5M |
| FY23 | $7.5M | −$526.2M |
| FY22 | $94.6M | −$389M |
| FY21 | $70.4M | −$215.3M |
| FY20 | $55.8M | −$127.3M |
| FY19 | $26.9M | −$121.7M |
| FY18 | $31.5M | −$106.3M |
| FY17 | $13.4M | −$127.8M |
| FY16 | $106.4M | $16.5M |
| FY15 | $28.7M | −$37.5M |
| FY14 | $46.9M | −$14.6M |
| FY13 | $30.6M | −$33.7M |
| FY12 | $7.6M | −$40.4M |
| FY11 | $4M | −$47.9M |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −695.4% | −891.6% |
| FY24 | −2902.7% | −3191.1% |
| FY23 | −6589.7% | −6988.6% |
| FY22 | −342.8% | −411.2% |
| FY21 | −264.5% | −305.7% |
| FY20 | −168.3% | −228% |
| FY19 | −368% | −452.9% |
| FY18 | −282.3% | −337.4% |
| FY17 | −848.3% | −955.9% |
| FY16 | 17.6% | 15.5% |
| FY15 | −130.5% | −130.9% |
| FY14 | −31.4% | −31.2% |
| FY13 | −110.6% | −110% |
| FY12 | −535.2% | −534.1% |
| FY11 | −1199.1% | −1196.5% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$534.8M |
| FY24 | −$399.8M |
| FY23 | −$415.7M |
| FY22 | −$310.9M |
| FY21 | −$191.4M |
| FY20 | −$2.1M |
| FY19 | −$93.5M |
| FY18 | −$102.1M |
| FY17 | −$104.6M |
| FY16 | $35.4M |
| FY15 | $4.3M |
| FY14 | −$45.9M |
| FY13 | −$8.3M |
| FY12 | −$33.6M |
| FY11 | −$46M |
- Cytokinetics
- Healthcare median
Show the numbers
| Year | Cytokinetics | Healthcare median |
|---|---|---|
| FY25 | −891.6% | −30.6% |
| FY24 | −3191.1% | −47% |
| FY23 | −6988.6% | −58% |
| FY22 | −411.2% | −80.4% |
| FY21 | −305.7% | −71.9% |
| FY20 | −228% | −62.2% |
| FY19 | −452.9% | −46.3% |
| FY18 | −337.4% | −49.6% |
| FY17 | −955.9% | −45.9% |
| FY16 | 15.5% | −36% |
| FY15 | −130.9% | −38.4% |
| FY14 | −31.2% | −35.5% |
| FY13 | −110% | −37.1% |
| FY12 | −534.1% | −29.1% |
| FY11 | −1196.5% | −27.9% |